Pain practice : the official journal of World Institute of Pain
-
Self-efficacy is one of the important factors affecting chronic diseases. In the current epidemiological context of low back pain (LBP), LBP self-efficacy has become a topic of great practical interest for researchers. However, no bibliometric analysis related to LBP self-efficacy has been performed to date. The purpose of this study was to conduct and explore the current state of research in LBP self-efficacy from 1980 to 2021, by using bibliometric analysis and scientific mapping. ⋯ The volume of literature on LBP self-efficacy has increased linearly over the past 41 years and will continue to increase. The field of study has become more refined. This bibliometric analysis provides valuable support for future directions and research trends in LBP self-efficacy.
-
Case Reports
Loss of effectiveness with an implanted drug delivery system for intrathecal pain therapy due to corrosion.
Intrathecal drug delivery is an established invasive treatment option. Most common complication is catheter malfunction, which can lead to overdose or withdrawal. ⋯ Recommendations on how to deal with the decreasing effectiveness of intrathecal drug delivery and on intraoperative catheter handling are provided.
-
Chronic low back pain can impact cognitive function. Patient can have decreased problem-solving abilities, decreased speed of information processing, and delayed memory in addition to the development of different psychological conditions. Treating chronic pain effectively can potentially reduce those negative effects and potentially improve patients' cognitive function.
-
Chronic pain can trigger both physical and mental health complications. During the COVID-19 pandemic, patients with chronic diseases have had reduced access to some medications. ⋯ The pharmacological management of patients with chronic pain is heterogeneous, and this real-world study showed that a high proportion of patients experienced an interruption of pain management during the 12 months following the onset of the COVID-19 pandemic.
-
To assess whether dual therapy with erenumab and onabotulinumtoxinA (BoNTA) was more effective than erenumab alone in chronic migraine. ⋯ Our findings suggest that dual therapy is less effective than erenumab alone. However, since the design has multiple limitations, further prospective studies are required to validate these data.